Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-16

Study Completion Date

2017-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single and multiple dose, parallel group study to assess safety and pharmacokinetics of oral HTL0018318 in healthy Japanese and Caucasian subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

NCT03501069

Healthy Volunteers

TERMINATED PHASE1

Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118

NCT01348724

Healthy Volunteers

COMPLETED PHASE1

Mass Balance Study of TS-142 in Healthy Adult Subjects.

NCT04814771

Healthy Male Subjects

COMPLETED PHASE1

A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects

NCT04182958

Healthy Adult Male

COMPLETED PHASE1

Study of Absorption, Metabolism and Excretion Following a Single Oral Dose of [14C]KWA-0711 to Healthy Male Subjects

NCT02434835

Healthy Male Subject

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single and multiple dose, parallel group study to assess safety and pharmacokinetics of oral HTL0018318 in healthy Japanese and Caucasian subjects. The study will be conducted in two parts: (A) single doses of HTL0018318 in healthy, adult, male Caucasian and Japanese subjects; (B) multiple doses of HTL0018318 in healthy, adult, male Caucasian and Japanese subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety Issues Pharmacokinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Part A open label, Part B double blind.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HTL0018318 Low dose, Part A.

Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).

Group Type ACTIVE_COMPARATOR

HTL0018318

Intervention Type DRUG

Part A single dose Part B five doses

HTL0018318 High dose, Part A

1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).

Group Type ACTIVE_COMPARATOR

HTL0018318

Intervention Type DRUG

Part A single dose Part B five doses

HTL0018318 Low dose, Part B

1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.

Group Type ACTIVE_COMPARATOR

HTL0018318

Intervention Type DRUG

Part A single dose Part B five doses

Placebo oral capsule, Part B

1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.

Group Type PLACEBO_COMPARATOR

Placebo oral capsule

Intervention Type DRUG

Part B only

HTL0018318 High dose, Part B.

1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.

Group Type ACTIVE_COMPARATOR

HTL0018318

Intervention Type DRUG

Part A single dose Part B five doses

Placebo oral capsule, Part B.

1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.

Group Type PLACEBO_COMPARATOR

Placebo oral capsule

Intervention Type DRUG

Part B only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HTL0018318

Part A single dose Part B five doses

Intervention Type DRUG

Placebo oral capsule

Part B only

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

placebo, placebo - cap

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male subjects, either Caucasian or Japanese aged ≥20 and ≤40 years.
2. Japanese subjects must have lived outside of Japan for ≤ 5 years in total and be first generation Japanese, defined as born in Japan and having 4 biologic grandparents who are ethnic Japanese.
3. The Caucasian subjects should be distinguished especially by very light to brown skin pigmentation and straight to wavy or curly hair, and should be indigenous to Europe, northern Africa and western Asia. Therefore, the study may include Caucasian subjects from North America, New Zealand, Australia and South Africa.
4. Subjects must have a body mass index (BMI) between 18.0-25.0 kg/m² inclusive.
5. Male subjects, if heterosexually active and with a female partner of childbearing potential or a pregnant or breastfeeding partner, must agree to use barrier contraception (male condom) for the treatment period and for at least 3 months after the end of the systemic exposure of the study drug.
6. Satisfactory medical assessment with no clinically significant or relevant abnormalities.
7. Able to perform spirometry/peak flow with a satisfactory technique at screening.
8. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the International Council of Harmonization Good Clinical Practice (GCP) Guideline E6.
9. An understanding, ability, and willingness to fully comply with study procedures and restrictions

Exclusion Criteria

1. Any history of any condition associated with cognitive impairment, including but not limited to schizophrenia and dementia.
2. History of epilepsy or seizures of any kind at any time.
3. Current or relevant history of any physical or psychiatric illness that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
4. The history or presence of any of the following cardiac conditions: known structural cardiac abnormalities; family history of long QT syndrome; cardiac syncope or recurrent, idiopathic syncope; exercise related clinically significant cardiac events.
5. Presence or history of drug or alcohol abuse in the last 5 years, or the inability to refrain from alcohol use from 48 hours before screening, dosing and each scheduled visit until the end of the study.
6. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, electronic cigarettes) within 3 months prior to the planned first day of dosing.
7. Use of prescription medications within 14 days or 10 half-lives (whichever is longer) prior to Day 1 of the dosing period, or any over-the-counter (OTC) medication (including multivitamin, herbal, or homeopathic preparations, excluding hormonal contraception, hormone-replacement therapy, and/or an occasional dose of acetaminophen) within 7 days prior to Day 1 of the dosing period.
8. History of significant allergic reaction (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc).
9. Has donated or lost 400 mL blood or more within the last 16 weeks preceding the first day of dosing.

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes